Catalog No.
PMJ41201
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse IL17F (Ala21-Ala161).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
Purification
Purified by antigen affinity column.
Accession
Q7TNI7
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Adipose-Derived Mesenchymal Stromal/Stem Cells Reduce Inflammatory Responses and Partially Alleviate Skin Symptoms in Imiquimod-Induced Psoriasis-Like Dermatitis Model Mice., PMID:40500215
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)., PMID:40358828
IL-17A, IL-17F, and IL-23 in Patients with Rheumatoid Arthritis., PMID:40353959
Assessing the clinical progress of the bispecific nanobody sonelokimab., PMID:40297934
Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein., PMID:40152593
Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation., PMID:40127522
Bimekizumab in the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis: A New Kid on the Block., PMID:40076933
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient., PMID:40016589
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab., PMID:39978685
Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions., PMID:39946257
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics., PMID:39925216
Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders., PMID:39875232
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period., PMID:39862230
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies., PMID:39798135
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study., PMID:39666087
Association of baseline cytokines with antibody concentrations after diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children., PMID:39616006
The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples., PMID:39531733
Amelioration of Systemic Amyloidosis by Blocking IL-17A and Not by IL-17F, and Arteriosclerosis by Blocking Both IL-17A and IL-17F in an Inflammatory Skin Mouse Model., PMID:39519167
Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study., PMID:39498997
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial., PMID:39493888
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review., PMID:39425925
Bimekizumab for the treatment of hidradenitis suppurativa., PMID:39297706
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies., PMID:39215949
Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study., PMID:39133570
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel., PMID:39093660
Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment., PMID:39093648
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial., PMID:39083288
Short-chain fatty acids ameliorate imiquimod-induced skin thickening and IL-17 levels and alter gut microbiota in mice: a metagenomic association analysis., PMID:39079980
IL-17A/F double producing T cells, unstable Tregs and quiescent TRMs in clinically healed lesions are potential cellular candidates for recurrence of psoriasis., PMID:39067676
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials., PMID:38977276
Biologics for Psoriasis., PMID:38796266
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials., PMID:38795716
Bimekizumab: A Review in Psoriatic Arthritis., PMID:38703349
Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature., PMID:38673523
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting., PMID:38662223
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland., PMID:38650583
Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis., PMID:38646719
Tumor necrosis factor alpha induced protein 3, interleukin 10, tumor necrosis factor alpha, and interleukin 17 F genes polymorphisms in Algerian patients with rheumatoid arthritis., PMID:38642181
Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders., PMID:38636269
Dual blockade of interleukin-17A and interleukin-17F as a therapeutic strategy for liver fibrosis: Investigating the potential effect and mechanism of brodalumab., PMID:38531177
Bimekizumab for the treatment of psoriasis., PMID:38506262
Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study., PMID:38482898
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials., PMID:38447700
Prevention of experimental autoimmune encephalomyelitis by targeting 6-sulfo sialyl Lewis X glycans involved in lymphocyte homing., PMID:38387051
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis., PMID:38253404
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis., PMID:38218744
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)., PMID:38073013
Biomass-related PM2.5 induced inflammatory microenvironment via IL-17F/IL-17RC axis., PMID:38036089
IL-17 receptor A functions to help maintain barrier integrity and limit activation of immunopathogenic response to H. pylori infection., PMID:38014948
Protective role of IL-17-producing γδ T cells in a laser-induced choroidal neovascularization mouse model., PMID:38007487
For research use only. Not for human or drug use.
